AIMS:To evaluate, the pharmacotherapeutic efficacy of Tizanidine hydrochloride and Gabapentin in patients with persistent myofascial pain and to identify patient and pain characteristics that may predict treatment outcome. METHODS: A stepped Pharmacotherapeutic protocol was employed. All 40 patients having persistent facial pain with tenderness of regional muscles were first prescribed Tizanidine hydrochloride. In patients where no response to Tizanidine hydrochloride was observed, Gabapentin was initiated. Outcome was assessed by employing prospective diaries recording pain intensity measured with an 11-point (0-10) Visual Analog scale (VAS). Individual characteristics in these patients and their influence on drug response and outcome were analyzed; specifically, patients treated with Tizanidine hydrochloride were compared with those subsequently treated with Gabapentin. Chisquare and t tests were used to analyze the data. RESULTS: A total of 22 patients responded to Tizanidine hydrochloride and continued on this regimen, while 18 were resistant to Tizanidine hydrochloride and were subsequently treated with Gabapentin. However when the comparison was done in the intra group pain intensity at the base line and at the end of 6 weeks it was seen that in the group 1 the mean value at the baseline was 6.3 and for group 2 the mean value at the baseline was 5.9 and at the mean value at the end of 6 weeks was 2.11 in group1 and 2.06 In group 2 which showed a significant improvement in the pain intensity in both the groups, significant statistical difference was noted with the, (P-value<0.05). Patients who did not respond to Tizanidine hydrochloride were characterized by a significantly higher age, more comorbid medical illness, and evidence of more regional pain spread. Overall, a stepped approach employing Tizanidine and gabapentin resulted in overall improvement in the treatment outcome.
CONCLUSION:This study has demonstrated the good pharmacotherapeutic response of persistent myofascial pain, even in more severe cases. Patients who do not respond to Tizanidine may be a distinct subgroup and this needs further investigation. The results also suggest that gabapentin, at a lower dose than previously reported, is a good alternative in Tizanidine hydrochloride resistant patients.